

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

Brilliant Violet 711(TM) anti-human CD3

RRID:AB_2566036

Type: Antibody

Proper Citation

BioLegend Cat# 300464, RRID:AB_2566036

Antibody Information

URL: http://antibodyregistry.org/AB_2566036

Proper Citation: BioLegend Cat# 300464, RRID:AB_2566036

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 711(TM) anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_2566036

Vendor: BioLegend

Catalog Number: 300464

Alternative Catalog Numbers: 300463

Record Creation Time: 20250820T054150+0000

Record Last Update: 20250820T221437+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 711(TM) anti-human CD3.

No alerts have been found for Brilliant Violet 711(TM) anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chen Y, et al. (2024) Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. *Cancer cell*, 42(7), 1268.

Reuschl AK, et al. (2022) HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory T cells. *Cell reports*, 39(2), 110650.

Georg P, et al. (2022) Complement activation induces excessive T cell cytotoxicity in severe COVID-19. *Cell*, 185(3), 493.

Kfoury Y, et al. (2021) Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. *Cancer cell*, 39(11), 1464.

Dupraz L, et al. (2021) Gut microbiota-derived short-chain fatty acids regulate IL-17 production by mouse and human intestinal ?? T cells. *Cell reports*, 36(1), 109332.

Litchfield K, et al. (2021) Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. *Cell*, 184(3), 596.

Berezhnoy A, et al. (2020) Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. *Cell reports. Medicine*, 1(9), 100163.